Question 1

What is AbbVie's P/FCF ratio?

Accepted Answer

AbbVie (ABBV) P/FCF ratio is 21.5× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month free cash flow, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/FCF ratio calculated?

Accepted Answer

P/FCF = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Free Cash Flow, where Free Cash Flow = Operating Cash Flow − Capital Expenditures. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/FCF ratio?

Accepted Answer

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.

Question 4

What is a good P/FCF ratio for AbbVie?

Accepted Answer

Mature companies that consistently convert profit into cash often trade at 15–25× P/FCF; capital-intensive businesses with lumpy capex typically trade lower. Compare against sector peers and against the company's own multi-year average — single-year P/FCF can be distorted by working-capital swings. For AbbVie specifically, the relevant sector benchmark is the current sector median of 19.1×.

Question 5

Is AbbVie's P/FCF ratio high or low?

Accepted Answer

AbbVie's P/FCF ratio of 21.5× is above its own 5-year average of 14.8× and above the sector median of 19.1×. That places the current reading at the 92th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is AbbVie's historical P/FCF ratio range?

Accepted Answer

In the available daily series, AbbVie (ABBV) P/FCF ratio has ranged from a low of 8.3× in 2020 to a high of 35.5× in 2014. The 5-year average is 14.8× and the 5-year median is 12.7×.

Question 7

What was AbbVie's P/FCF ratio in 2025?

Accepted Answer

AbbVie (ABBV) P/FCF ratio at the end of 2025 was 21.8×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month free cash flow figure available at that date.

Question 8

Why does AbbVie's P/FCF ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (free cash flow). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$407B	$18.7B	21.8×	+4.1×	Dec 31, 2025
2024	$314B	$17.8B	17.6×	+5.2×	Dec 31, 2024
2023	$274B	$22.1B	12.4×	+0.6×	Dec 31, 2023
2022	$286B	$24.2B	11.8×	+0.9×	Dec 31, 2022
2021	$239B	$22B	10.9×	-0.4×	Dec 31, 2021
2020	$190B	$16.8B	11.3×	+1.0×	Dec 31, 2020
2019	$131B	$12.8B	10.3×	-0.4×	Dec 31, 2019
2018	$137B	$12.8B	10.7×	-5.6×	Dec 31, 2018
2017	$154B	$9.43B	16.3×	+1.1×	Dec 31, 2017
2016	$99.7B	$6.56B	15.2×	+1.6×	Dec 31, 2016
2015	$95.4B	$7B	13.6×	-21.8×	Dec 31, 2015
2014	$104B	$2.94B	35.5×	+20.9×	Dec 31, 2014
2013	$83.8B	$5.78B	14.5×	+5.5×	Dec 31, 2013
2012	$54.1B	$6.01B	9.0×	-0.4×	Dec 31, 2012
2011	$55.3B	$5.89B	9.4×	—	Dec 31, 2011


McKesson (MCK)	17.8×
Gilead Sciences (GILD)	16.9×
DexCom (DXCM)	16.9×
Pfizer (PFE)	16.7×
Humana (HUM)	16.4×
Quest Diagnostics (DGX)	16.3×
UnitedHealth Group (UNH)	15.9×
Labcorp Holdings (LH)	15.9×
Becton, Dickinson and (BDX)	14.0×
HCA Healthcare (HCA)	13.5×
Elevance Health (ELV)	13.4×
Incyte (INCY)	12.9×
CVS Health (CVS)	12.4×
Universal Health Services (UHS)	12.2×
Baxter International (BAX)	12.1×
Cardinal Health (CAH)	11.3×
IQVIA (IQV)	11.3×
Bristol-Myers Squibb (BMY)	10.4×
Biogen (BIIB)	10.3×
Zimmer Biomet Holdings (ZBH)	9.6×
Cigna (CI)	9.1×
Viatris (VTRS)	9.1×
DaVita (DVA)	6.9×
Teladoc Health (TDOC)	3.9×
Centene (CNC)	2.5×

P/FCF Ratio for AbbVie (ABBV) 2011-2026

P/FCF Ratio daily chart for AbbVie (ABBV)

Historical P/FCF Ratio for AbbVie (ABBV) from 2011 to 2025

About P/FCF Ratio at AbbVie (ABBV)

AbbVie P/FCF Ratio by Year

AbbVie P/FCF Ratio 2025: 21.8×

AbbVie P/FCF Ratio 2024: 17.6×

AbbVie P/FCF Ratio 2023: 12.4×

AbbVie P/FCF Ratio 2022: 11.8×

AbbVie P/FCF Ratio 2021: 10.9×

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

AbbVie (ABBV) Key Financials